Evidence map›Paper›PMID 41674806›Full record

ArticleResearch square2026

Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor.

Stephen D Carro, Emma J Hedgepeth, Candy Lucero-Sanchez, Mary K Heard, Angela R Corrigan, Heejoon M Shin, Elise M Peauroi, Laurence C Eisenlohr

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stephen D CarroDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA.
Emma J HedgepethDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA 19104, USA.
Candy Lucero-SanchezDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA 19104, USA.ORCID 0009-0007-4858-6943
Mary K HeardDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA 19104, USA.ORCID 0000-0002-5151-5675
Angela R CorriganDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA.
Heejoon M ShinDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania; Philadelphia, PA 19104, USA.ORCID 0009-0004-6621-4551
Elise M PeauroiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA.
Laurence C EisenlohrDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA.ORCID 0000-0002-8475-7910

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
The B22 family of orthopoxvirus virulence factors: Investigating structure/function of these potent, multifaceted immunoevasinsR01AI182049 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI Laurence Crane Eisenlohr · 2024 to 2026
$2.2M
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 proteinR21AI160063 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI EISENLOHR, LAURENCE CRANE · 2021 to 2022
$484k
Uncovering the molecular underpinnings of C15, a potent orthopoxvirus virulence factorF31AI183694 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CARRO, STEPHEN DAVID · 2024 to 2024
$37k
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS F31 AI183694NIAID NIH HHS R01 AI182049NIAID NIH HHS R21 AI160063NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Orthopoxviruses, including variola and monkeypox, have long ravaged human populations for reasons that remain unclear. Members of the highly conserved B22 protein family are notable for their extreme virulence via targeting of multiple host defenses. C15, the B22 protein of ectromelia (murine model for smallpox), is known to target NK cells and CD4+ T cells, and, as shown here, also CD8+ T cells. Unexpectedly, in C57Bl/6 mice, T cell responses were larger, more functional, and phenotypically enhanced in the face of C15 expression. cDC1-mediated cross-presentation contributed to enhanced CD8+ T cell responses, but the primary contributor was C15-mediated antagonism of NK cell-dependent viral control, and single cell analysis identified a potential signaling scaffold downstream of C15 inhibitory activity. Conversely, in BALB/c mice, which mount suboptimal NK cell responses, T cells were more prominently inhibited. These studies introduce the concept of conditional immunomodulation dictated by the immunocompetence profile of the host.

Identifiers

PMID41674806
PMCPMC12889813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.